Kornimate/medical-research-clean huggingface dataset:
k301 for the treatment of seborrhoeic eczema (se) of the scalp

Conditions: Seborrhoeic Eczema of the Scalp

Summary: seborrhoeic eczema (se) is a chronic, inflammatory skin disorder confined to areas of the head and trunk where sebaceous glands are most prominent. the severity varies from mild dandruff to exfoliative erythroderma that ranges from mild, patchy scaling to widespread, and thick, adherent crusts. the worldwide prevalence of se is 3-5%, although dandruff, the mildest form of the disorder affects up to 15-20% of the population. in this multicentre, randomised, double-blind, placebo-controlled phase iii study, adult se patients are treated once daily for 4 weeks. the population for this study is patients with mild to moderate se. the primary endpoint for this study is the efficacy of k301 compared to placebo which was based on the sum score for erythema and desquamation after 4 weeks of daily application. secondary endpoints are to evaluate safety and tolerability as well as efficacy.


Eligibility criteria:
inclusion criteria: * male or female (including fertile women) * 18-70 years of age * seborrhoeic eczema of the scalp for at least 2 months * presenting erythema and desquamation of mild to moderate intensity * signed written informed consent exclusion criteria: * seborrhoeic eczema or any other cutaneous disease of the face or scalp requiring a specific topical treatment (corticosteroids, antifungals, selenium sulphide, antibiotics, retinoids, benzoyl peroxide or a-hydroxyacids) during the previous 15 days * oral treatment with cyclines, lithium, antifungals or inhaled corticosteroids during the previous month * use of systemic corticosteroids and retinoids during the previous 2 months * seborrhoeic eczema associated with parkinson's disease or hiv infection * current or any history of ear, nose, and throat carcinoma * current or any history of severe concomitant disease according to investigator's judgement * allergy to any of the tested treatment components * subject who has been previously enrolled in the phase ii study k40-3 investigating kaprolac® k40

Keywords: seborrhoeic eczema scalp dandruff k301 k40
internet-delivered cbt for adolescents with ocd: a randomized controlled study

Conditions: Obsessive-Compulsive Disorder

Summary: the effect of internet-delivered cognitive behavior therapy (icbt) on adolescents (12 to 17 years) with obsessive-compulsive disorder is studied. participants are randomized to either icbt or a no-treatment condition. we expect icbt to be superior over the no-treatment condition.

the primary objective of this study is to test the efficacy of internet-delivered cognitive behavior therapy (icbt) for adolescents (12 - 17 years) with ocd. we aim to conduct a randomized controlled study with n = 66 participants. participants will be randomly assigned to icbt or a wait list condition, either lasting 12 weeks. the primary outcome measure is the children's yale-brown obsessive compulsive scale (cy-bocs). study participants will be followed up 3 and 12 months after treatment. icbt is expected to yield significantly better symptom reduction than the wait list condition.

Eligibility criteria:
inclusion criteria: * a primary diagnosis of ocd as defined by dsm-5 * a total score of ≥ 16 on the children's yale-brown obsessive-compulsive scale, cy-bocs * age between 12 and 17 years * ability to read and write swedish * daily access to the internet * a parent that is able to co-participate in the treatment * participants on psychotropic medication must have been on a stable dose for the last 6 weeks prior to baseline assessment exclusion criteria: * diagnosed autism spectrum disorder, psychosis or bipolar disorder, severe eating disorder * suicidal ideation * ongoing substance dependence * subject not able to read or understand the basics of the icbt material * completed cbt for ocd within last 12 months (defined as at least 5 sessions of cbt including exposure and response prevention) * ongoing psychological treatment for ocd or another anxiety disorder

Keywords: ocd adolescents pediatric internet online cbt
canadian cohort of convective thermal therapy using rezūm system in benign prostatic hyperplasia (bph).

Conditions: Urologic Diseases

Summary: to document the clinical outcome of rezūm therapy for bph patient in canadian cohort.


Eligibility criteria:
inclusion criteria: * male subjects of ≥ 18 years of age. * primary diagnosis of benign prostate hypertrophy (bph). * candidate for rezūm therapy as per clinical decision of investigator. * willing and able to accurately complete the required questionnaires. * willing and able to provide signed and dated informed consent exclusion criteria: * characteristics indicating a poor compliance with study protocol requirements. * disease or other health condition that is not suitable for this study. * unable or unwilling to provide signed informed consent.

Keywords: benigh prostate hypertrophy
value of mifepristone in cervical preparation prior to dilation and evacuation 19-24 weeks

Conditions: Abortion, Induced

Summary: a common practice for preparation for surgical abortion after 19 weeks gestation is the placement of multiple sets of osmostic dilators 1-2 days prior to the procedure. the investigators aim to study the addition of mifepristone as an adjunct to cervical dilation prior to abortion between 19-24 weeks gestation, and its potential to minimize the number of painful procedures and time in clinic (or away from work/home) that multiple sets of dilators can require. the investigators hypothesize that one set of dilators with mifepristone will result in similar procedure times and decreased "total" time as two sets of dilators.


Eligibility criteria:
inclusion criteria: * \>18 years old * viable, singleton pregnancy * voluntarily seeking abortion between 19 and 24wks gestation * able to give informed consent and comply with study protocol * fluent in english or spanish exclusion criteria: * allergy to misoprostol or mifepristone

Keywords: mifepristone induced abortion dilation and evacuation cervical preparation osmotic dilators
a clinical trial to prevent new onset diabetes after transplantation

Conditions: Prevention of New Onset Diabetes Among Kidney Transplant Patients

Summary: specific aim 1: to determine the clinical efficacy of early initiation of insulin therapy in decreasing the incidence of nodat among de novo kidney transplant patients with manifested post-transplant hyperglycemia during the first week after transplantation. hypothesis 1: early initiation of insulin therapy protects beta-cell from early stress related to the surgery and use of higher doses of immunosuppressive medications, and leads to lower incidence of nodat at 1 and 2 years. specific aim 2: to determine the improvement in overall glycemic control with the early initiation of insulin therapy. hypothesis 2: early initiation of insulin therapy results in greater overall control of glycemia compared to standard care of dietary counseling, life-style modification, oral hypoglycemic agents and/or insulin as needed at 1 year. specific aim 3: to determine the improvement in beta-cell function among patients assigned to the early initiation of insulin therapy at one year post-transplantation. hypothesis 3: early initiation of insulin therapy protects beta-cell from glucotoxicity of post-transplant hyperglycemia and preserves better beta-cell function at 1 year.


Eligibility criteria:
inclusion criteria: 1. adult patients (\> 18 years) with end stage renal disease (esrd) undergoing kidney transplantation; 2. standard triple immunosuppressive medications following kidney transplantation including tacrolimus, mycophenolate mofetil and corticosteroids; 3. capable to understand the study protocol and to give informed consent; exclusion criteria: 1. type 1 and 2 diabetes mellitus (dm) either as co-morbidity or cause of esrd;

Keywords: kidney transplant new onset diabetes prevention insulin
outcomes of functional substrate mapping of ventricular tachycardia

Conditions: Ventricular Tachycardia

Summary: the goal of this registry database is to demonstrate the safety and effectiveness of functional ventricular tachycardia (vt) ablation using sense protocol in patients with ischaemic vt. mortality and the need for icd therapies at 12 months post-ablation will be compared with propensity-matched controls undergoing substrate-based ablation alone.

this is an international multicentre prospective registry. participating centres will collect data during the pre-assessment, procedure, and follow-up visits at 6 and 12 months, according to standard practice. it is anticipated that the enrolment duration will be approximately 12 months, with the data being matched with that collected from a control group of patients undergoing conventional ventricular tachycardia ablation methods.

Eligibility criteria:
inclusion criteria: one of the following vt events (within the last 6 months) + ejection fraction \<40%: a: ≥3 episodes of vt treated with anti-tachycardia pacing (atp), at least one of which is symptomatic. b: ≥1 appropriate icd shock. c: ≥3 vt episodes within 24 hr. d: sustained vt below the detection rate of the icd. exclusion criteria: * contraindication to vt ablation * renal failure (crcl \< 15 ml/min) * nyha iv or ccs iv angina * stemi within 1 month * cabg within 3 months * pci within 1 month * pregnant * life expectancy \< 1 year
post marketing surveillance study of dysport

Conditions: Blepharospasm; Hemifacial Spasm; Cervical Dystonia; Spasmodic Torticollis; Cerebral Palsy; Muscle Spasticity; Cerebrovascular Accident; Equinus Deformity; Facial Hyperdynamic Lines

Summary: the purpose of this study is to provide further information regarding the risks and benefits of dysport in marketed indications.


Eligibility criteria:
inclusion criteria: * adult or child over the age of 2 years * scheduled to receive dysport as per their normal treatment practice, and in conformance with their country's summary of product characteristics exclusion criteria: * history of hypersensitivity to dysport or drugs with a similar chemical structure * treatment with any other investigational drug within the last 30 days before survey entry
clinical study of the third dose immunization schedule of covid-19 inactivated vaccine, (vero cells) in adults aged 18 years and above

Conditions: SARS-CoV2 Infection

Summary: to evaluate the immunogenicity and safety of the third dose sars-cov-2 vaccine, inactivated (vero cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule of institute of medical biology chinese academy of medical sciences sars-cov-2 inactivated vaccine.


Eligibility criteria:
inclusion criteria: 1. axillary temperature ≤37.0 ℃. 2. aged 18 years and above, after 3, 4, 5, or 6 months since finished two doses schedule of institute of medical biology chinese academy of medical sciences sars-cov-2 inactivated vaccine. 3. proven legal identity, could come each visit. 4. participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form. exclusion criteria: 1. persons with a clear history of sars-cov-2 infection. 2. using blood products after basic immunization or receiving immunosuppressive therapy. 3. participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 6 months after vaccination. 4. allergic to the active substance in the vaccine, any inactive substance or substance used in the preparation process (aluminum hydroxide, glycine); 5. history of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors. 6. diseases beyond drug control, such as high blood pressure, diabetes, asthma. 7. those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days. 8. immunization with any vaccine within 14 days. 9. any other situations judged by investigators as not suitable for participating in this study.
investigation on home care needs of als patients and their caregivers

Conditions: Amyotrophic Lateral Sclerosis

Summary: the research target 1. to investigate the home nursing knowledge needs of als patients; 2. investigate the needs of als caregivers for home nursing knowledge; 3. to compare the differences between patients and caregivers in the knowledge needs of patients' refusal to care, so as to provide patients and caregivers with targeted care, meet the needs of patients, improve the quality of life of patients, and extend the survival period.

the research target 1. to investigate the home nursing knowledge needs of als patients; 2. investigate the needs of als caregivers for home nursing knowledge; 3. to compare the differences between patients and caregivers in the knowledge needs of patients' refusal to care, so as to provide patients and caregivers with targeted care, meet the needs of patients, improve the quality of life of patients, and extend the survival period. assessment indicators 1. scale: self-designed questionnaire "questionnaire on the degree of home nursing knowledge needs of als patients or their families"; 2. amyotrophic lateral sclerosis function rating scale (als frs)

Eligibility criteria:
inclusion criteria: * confirmed and suspected patients of als diagnostic criteria revised by e1 escorial in 1998;conscious and stable vital signs;signing the informed consent; exclusion criteria: * patients with severe medical diseases, such as severe cardiovascular and cerebrovascular diseases, liver and kidney failure, etc.the existing resources cannot complete the questionnaire to fill in the exclusion of patients, but the caregivers can fill in the questionnaire;
can we predict who has gastroesophageal reflux disease (gerd)?

Conditions: Gastroesophageal Reflux Disease

Summary: gastroesophageal reflux disease (gerd) is currently defined as "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications". doctors often diagnose and treat gerd based on symptoms of heartburn and regurgitation. in recent years, the prevalence of partial or non-response to proton pump inhibitors (ppi) has increased resulting in diagnostic testing with esophagogastroduodenoscopy (egd) or ambulatory ph monitoring. most patients do not have endoscopic evidence for reflux. thus, in this group ph monitoring has emerged as an important physiologic test to determine the degree of esophageal acid exposure and to assess the association between patients' persistent symptoms and acid reflux events. the aims of this study are to assess the sensitivity and specificity of symptom associated indices and determine the best parameter for predicting gerd from a list of conventional ph measurement findings.


Eligibility criteria:
inclusion criteria: * male and female subjects ages 18 or older * presenting to the vanderbilt gi outpatient clinic with symptoms of gerd * undergoing upper endoscopy and wireless ph monitoring (standard of care) * erosive disease: presence of esophageal mucosal injuries documented * non-erosive disease: normal esophagogastroduodenoscopy (egd) with symptoms * control group: normal subjects without symptoms of gerd exclusion criteria: * anti-reflux therapy within 7 days prior to the ph study * previous neck, esophagus, or stomach surgery * major motility disorders * previous neck, esophagus, or stomach cancer or radiations

Keywords: reflux gastroesophageal reflux disease gerd
clinical trial with adipose tissue stem cells on biological matrix for the treatment of venous ulcer of the lower limbs

Conditions: Venous Ulcer

Summary: phase i-ii, multicenter, randomized, controlled, proof of concept clinical trial to determine feasibility, safety and efficacy of the use of allogenic adipose-derived adult mesenchymal stem cells expanded on fibrinhyaluronic biological matrix in the treatment of venous ulcer of the lower limbs.


Eligibility criteria:
inclusion criteria: 1. signing of the informed consent (ic) after reading the patient information sheet. 2. over 18 years of both sexes. 3. active or recurrent venous ulcer in the lower extremity with an area between 5-10 cm2 4. grade iii injury on the widmer scale. 5. independence and/or availability to go to the referral center on an outpatient basis. 6. distal pulses in palpable lower limbs (tibial and foot). abi between 0.8 - 1.3 exclusion criteria: 1. any pathology for which the investigator considers that compression bandaging is contraindicated and/or previous acute deep vein thrombosis (dvt), within the first 10 days from the onset of symptoms. 2. grade iii obesity with a body mass index (bmi) \>40; or underweight patients (bmi \<18.5). 3. active neoplasia and/or being treated with cytostatics. 4. patients undergoing radiotherapy treatment in areas close to the lesion. 5. clinical signs of colonization or local infection of the lesion. 6. patients with more than one lesion compatible with uv in the same lower limb. 7. erysipelas. 8. infectious cellulite. 9. osteomyelitis. 10. lymphangitis. 11. chronic lymphedema. 12. therapy with corticosteroids or immunosuppressants. 13. venous ulcer grade i or ii on the widmer scale. 14. lesions close to possible or diagnosed cancerous lesions. 15. non-localized wounds in the lower extremities. 16. ongoing infection and/or sepsis. 17. critical ischemia in the lower limbs or other venous diseases of unknown origin. 18. immunocompromised patients. 19. dependent patients with severe mobility limitations. 20. dialysis patients.
mandibular reconstruction bone plate

Conditions: Mandible Tumor

Summary: the purpose of this study is to evaluate the reliability of using mandibular osteosynthesis a 2.3mm reconstruction bone plate in the maintenance of the space, contour, and mandibular bone preservation during marginal mandibular resection.

this prospective study included 16 patients (n=16) suffering from presence of mandibular central benign lesions indicated for marginal mandibular resection. patient history included personal data (name, age, sex, and occupation), date of lesion discovery, mode of growth (rapid or slow), and symptoms (e.g. pain and/or ipsilateral paresthesia of the lower lip). clinical examination included the site and extent of mandibular bony expansion and covering soft tissues (normal, ulcerated from indentation of opposing teeth, or scarred due to previous incisional biopsy). radiographical examination involved orthopantomography (opg) and axial and coronal computed tomography (ct) scans to assess the lesion extensions. all patients are operated under general anesthesia which was induced by intravenous access. intubation is routinely performed in nasoendotracheal fashion. intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins are carried out around the teeth to be included in the resection. the plastic template is adapted to the buccal cortex of the mandible to aid in the final adaptation of a 2.3 mm reconstruction bone plate (antonhib, germany). the osteotomy lines are marked using a long shank surgical tapered fissure bur. a 2.3 mm reconstruction bone plate is then fit in place and fixed to both the proximal and distal segments then removed. the osteotomies completed and the resected segment is removed, and the reconstruction plate is then replaced by the aid of screw holes in both the proximal and distal segments. the intraoral wound is carefully closed in double layers using a combination of interrupted and horizontal mattress resorbable 3/0 sutures. post operative follow up clinically regarding soft tissue healing, pain, infection, and plate exposure or plate fracture. radiographically, panoramic radiographs are taken immediately and axial and coronal computed tomography at six months post-operatively.

Eligibility criteria:
inclusion criteria: * patients suffering from presence of mandibular central benign lesions indicated for marginal mandibular resection exclusion criteria: * systemic disease affect primary wound healing malignancy

Keywords: reconstruction bone plate mandible
pianzumab combined with avd regimen in the treatment of newly-diagnosed advanced classic hodgkin lymphoma

Conditions: Classic Hodgkin Lymphoma

Summary: this study is conducted to evaluate the safety and efficiency of penpulimab combined with avd in patients with newly- diagnosed advanced classic hodgkin lymphoma.


Eligibility criteria:
inclusion criteria: 1. age: 18-70 years old (when signing the informed consent form); ecog score: 0 or 1 point; the expected survival period exceeds 3 months; 2. classic hodgkin lymphoma (chl) confirmed by histopathology; 3. the subject must be advanced patient, specifically defined as ann arbor stage iii-iv or iib with any of the following high-risk factors: ① maximum diameter of mediastinal mass/maximum diameter of thoracic cavity\>0.33; ② there are large masses with a diameter of\>10cm; 4. have not received systemic anti classic hodgkin lymphoma treatment; 5. measurable disease ; 6. adequate main organs function 7. female subjects of childbearing age should agree to use contraceptives (such as intrauterine device, contraceptives or condoms) during the study period and within 6 months after the end of the study; the serum or urine pregnancy test was negative within 7 days before the study was included, and must be non-lactating subjects; male participants should agree to use contraception during the study period and within 6 months after the end of the study period. exclusion criteria: 1. nodular lymphocyte dominated hodgkin lymphoma or gray area lymphoma; 2. classic hodgkin lymphoma involves the central nervous system; 3. subjects who have or are suspected to have active autoimmune diseases within the past 2 years, or have previously suffered from autoimmune diseases and are currently at high risk of recurrence and require systemic treatment； 4. subjects who need to use glucocorticoid (\>10mg/day prednisone equivalent dose) or other immunosuppressive drugs for systemic treatment within 14 days before the first administration. 5. inoculate or expect to receive live or attenuated live vaccines or mrna vaccines within 4 weeks before the first administration; 6. received allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 7. known to have active pulmonary tuberculosis; 8. having a history of immunodeficiency, including hiv positive or suffering from other acquired or congenital immunodeficiency diseases; 9. subjects with a known history of interstitial pneumonia, a history of non-infectious pneumonia, or highly suspected cases of interstitial pneumonia; 10. patients with evidence of bleeding constitution or medical history; within 4 weeks before the first medication, any ≥ ctc ae level 3 bleeding events (such as digestive tract bleeding, perforation, etc.) occur; 11. concomitant diseases and medical history: 1. has experienced or currently suffers from other malignant tumors within 3 years. 2. multiple factors affecting oral medicine (such as inability to swallow, chronic diarrhea and bowel obstruction); 3. patients with a history of abuse of psychotropic substances who are unable to quit or have mental disorders; 4. subjects with any severe and/or uncontrollable disease.